Candel Therapeutics, Inc. Common Stock (CADL) Stock
Key stats
- Market cap
- $705.50M
- Price / Earnings ratio
- -8.1x
- EPS (TTM)
- -$1.42
- Volume
- Loading
- 52-week high
- $14.00
- 52-week low
- $4.35
Source: third-party data provider, as of November 13, 2026
Compare with CADL
Recent news

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
CADL

Dow, S&P 500, Nasdaq Futures Edge Higher After Fed Delivers Rate Hike: SPCX, CADL, SNAP, FLNC Stocks In Focus
Dow, S&P 500, Nasdaq Futures Edge Higher After Fed Delivers Rate Hike: SPCX, CADL, SNAP, FLNC Stocks In Focus
CADL

4 Prostate Cancer Drug Stocks to Watch During Awareness Month
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
CADL

CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
CADL
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 51.21
- MACD 12/26/9
- -0.20
- EMA 9 of MACD
- -0.41
- MACD histogram
- 0.21
- SMA 50
- $9.99
- Price below SMA 50
- EMA 50
- $9.56
- Price below EMA 50
- SMA 200
- $8.39
- Price above SMA 200
- EMA 200
- $8.27
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
CADL

Dow, S&P 500, Nasdaq Futures Edge Higher After Fed Delivers Rate Hike: SPCX, CADL, SNAP, FLNC Stocks In Focus
Dow, S&P 500, Nasdaq Futures Edge Higher After Fed Delivers Rate Hike: SPCX, CADL, SNAP, FLNC Stocks In Focus
CADL

4 Prostate Cancer Drug Stocks to Watch During Awareness Month
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
CADL

CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
CADL

CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity
CADL

Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
CADL

CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’
CADL

CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish
CADL

Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data
CADL

Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
CADL
News tone: automated (AI) classification of the article's content, not a price prediction.
About Candel Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, CEO & Director | 1960 |
| Mr. Charles Schoch | Senior VP, CFO, Treasurer & Secretary | 1985 |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer | 1978 |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Development Officer | 1968 |
| Ms. Ileen B. Winick | Chief People Officer | — |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer | 1961 |
| Dr. William Nichols Garrett M.D., M.S. | Chief Medical Officer | 1969 |
| Mr. Mark Sims | Chief Commercial Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.21
- MACD 12/26/9
- -0.20
- EMA 9 of MACD
- -0.41
- MACD histogram
- 0.21
- SMA 50
- $9.99
- Price below SMA 50
- EMA 50
- $9.56
- Price below EMA 50
- SMA 200
- $8.39
- Price above SMA 200
- EMA 200
- $8.27
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $18.00
- Average
- $21.50
- High
- $25.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.5 | -18.6 | ||||||||||
| 2022 | -46.4 | -8.0 | +26.6 | -31.8 | -1.8 | -13.4 | -3.4 | +13.8 | -10.3 | -39.4 | -7.9 | -0.6 |
| 2023 | +45.2 | -25.3 | -27.4 | -8.5 | +11.0 | -16.6 | -13.6 | +16.2 | -24.0 | -13.5 | +0.0 | +63.3 |
| 2024 | -10.3 | +40.9 | -7.1 | +302.9 | +11.5 | -25.9 | -5.9 | +21.8 | +9.8 | -24.6 | -10.8 | +89.9 |
| 2025 | -21.4 | +25.6 | -28.6 | -11.8 | +11.5 | -9.5 | +33.0 | -7.9 | -13.0 | -2.9 | -8.6 | +26.1 |
| 2026 | +7.4 | -10.6 | -4.1 | +24.1 | +28.3 | +21.0 | +1.3 | +29.8 | -18.8 | -18.0 | +13.5 |



